U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday.Shares of Methode Electronics, Inc. MEI fell sharply in today's pre-market trading after the company reported a fourth-quarter adjusted EPS miss.Methode Electronics posted adjusted loss of 77 cents per share, missing market estimates of earnings of 4 cents per share, according to data from Benzinga Pro. The company' sales came in at $257.10 million versus estimates of $232.87 million.Methode Electronics sh ...

"Of the 28 million Americans with AUD, over 6 million have progressed to ALD, a condition for which there are no approved treatments and few in development," said Dr. Loomba. "Alcohol-related liver mortality is highest in patients with comorbid obesity, highlighting the urgent need for a liver-directed therapy that can also drive weight loss. The robust reductions in body weight, liver fat and VCTE and the low rates of adverse event discontinuation in the recently completed IMPACT Phase 2b MASH trial suppor ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Altimmune, Inc. and its officers or directors following the release of trial results that led to a significant drop in the company's stock price [1][3]. Group 1: Company Overview - Altimmune, Inc. is a publicly traded company on NASDAQ under the ticker symbol ALT [1]. - The company recently announced "topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH)" [3]. Group 2: Trial Results - The trial results were described as "positive," but the key efficacy endpoint showed fibrosis improvement rates of 31.8% and 34.5% for pemvidutide doses of 1.2 mg and 1.8 mg, respectively, compared to 25.9% for placebo, with differences not being statistically significant [3]. - Following the announcement of these results, Altimmune's stock price fell by $4.10 per share, representing a decline of 53.18%, closing at $3.61 per share on June 26, 2025 [3]. Group 3: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of investors regarding potential securities fraud or other unlawful practices by Altimmune and its management [1]. - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud [4].

Core Viewpoint - Altimmune, Inc. is under investigation for potential securities fraud following the release of mixed results from a clinical trial, which led to a significant drop in its stock price [1][2]. Group 1: Investigation and Legal Context - Pomerantz LLP is investigating claims on behalf of investors of Altimmune regarding possible securities fraud or unlawful business practices by the company and its officers or directors [1]. - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [3]. Group 2: Clinical Trial Results and Market Reaction - On June 26, 2025, Altimmune announced "topline results" from the IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), describing the results as "positive" [2]. - The trial reported fibrosis improvement rates of 31.8% and 34.5% for pemvidutide doses of 1.2 mg and 1.8 mg, respectively, compared to 25.9% for placebo, with the differences not being statistically significant [2]. - Following the announcement, Altimmune's stock price fell by $4.10, or 53.18%, closing at $3.61 per share on the same day [2].

Core Insights - Altimmune, Inc. released topline results from the IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease [1] Group 1: Trial Details - The Phase 2b trial included 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3, randomized to receive either weekly subcutaneous pemvidutide at 1.2 mg or 1.8 mg doses, or placebo for 24 weeks [2] - Treatment discontinuation rates were low, with only 9% of participants prematurely discontinuing treatment [3] Group 2: Efficacy Results - In an intent-to-treat (ITT) analysis, the proportions of participants achieving MASH resolution without worsening of fibrosis at 24 weeks were 59.1% for pemvidutide 1.2 mg, 52.1% for 1.8 mg, and 19.1% for placebo (p< 0.0001 for both doses) [3] - The effects on fibrosis improvement without worsening of MASH were 31.8% for pemvidutide 1.2 mg, 34.5% for 1.8 mg, compared to 25.9% for placebo, although these differences were not statistically significant [4] Group 3: Analyst Ratings - HC Wainwright reiterated a Buy rating for Altimmune with a price forecast of $12, believing the data supports advancing pemvidutide to Phase 3 and strengthens its case as a potential best-in-class therapy [5] - Conversely, William Blair maintained a Market Perform rating, citing "underwhelming" results and concerns about demonstrating significant fibrosis improvement at the 48-week mark [6] Group 4: Stock Performance - ALT stock is trading lower by 1.80% to $3.545 at last check [7]

整理 | GLP1减重宝典内容团队 Altimmune, Inc.公司今日公布了其候选药物pemvidutide在代谢相关脂肪性肝炎（MASH）治疗中IMPACT 2b期临床试验的积极初步结 果。然而，其疗效令投资人失望，股价一夜之间腰斩。 | 3.610+ | 最 昌 | 3.830 今 开 | 2.98 | | --- | --- | --- | --- | | -4.100 -53.18% | 最 低 | 2.900 昨 收 | 7.71 | | 成交额 3.05亿 市盈率TTM | | 亏损 总市值 → | 2.931 | | 成交量 8611.55万股 市盈率(静) | | 亏损 总股本 | 81117 | | 107.07% 市净率(1) 换手率 | | 2.06 流通值 | 2.901 | | 52周最高 11.160 委 比 | | 59.32% 流通股 | 80437 | | 52周最低 2.900 量 比 | | 14.72 振 幅 | 12.069 | | 历史最高 978.000 股息TTM | | -- 平均价 | 3.54 | | 历史最低 -1731.000 股息率TTM | N ...

ATLANTA, June 26, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) complied with federal securities laws. On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), revealing that the trial did not demonstrate statistical significance for the endpoint of improving fibrosis while not worsening MASH. Following this news, the pri ...

Core Insights - Altimmune, Inc. announced positive topline results from the IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), demonstrating significant MASH resolution and weight loss at 24 weeks [2][4][5] Study Results - The Phase 2b trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3, randomized to receive either weekly subcutaneous pemvidutide at 1.2 mg or 1.8 mg doses or placebo for 24 weeks [3][10] - In an intent-to-treat (ITT) analysis, MASH resolution without worsening of fibrosis was achieved in 59.1% and 52.1% of participants treated with pemvidutide 1.2 mg and 1.8 mg, respectively, compared to 19.1% for placebo (p< 0.0001) [3][7] - Fibrosis improvement without worsening of MASH was observed in 31.8% and 34.5% of participants treated with pemvidutide 1.2 mg and 1.8 mg, respectively, versus 25.9% for placebo [3][7] - Weight loss at 24 weeks was 5.0% for the 1.2 mg group and 6.2% for the 1.8 mg group, compared to 1.0% in the placebo group (p< 0.001) [3][7] - Liver fat reductions of 58.0% and 62.8% were achieved in participants receiving pemvidutide 1.2 mg and 1.8 mg, respectively, versus 16.2% in the placebo group (p< 0.001) [7][8] Safety and Tolerability - Pemvidutide demonstrated potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events [2][4] - Adverse events leading to treatment discontinuation were 0.0% and 1.2% for pemvidutide 1.2 mg and 1.8 mg, respectively, compared to 2.4% in the placebo group [3][7] Future Outlook - The company anticipates a successful End of Phase 2 meeting with the FDA in the fourth quarter of 2025, enabling rapid progression to Phase 3 [5][4] - The ongoing IMPACT trial is expected to provide a final readout in the fourth quarter of 2025 [10]

Core Viewpoint - Altimmune, Inc. is set to present topline data from its IMPACT Phase 2b trial evaluating pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH) on June 26, 2025 [1][2]. Group 1: Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases [5]. - The company's lead program, pemvidutide, is a GLP-1/glucagon dual receptor agonist aimed at treating MASH, obesity, Alcohol Use Disorder (AUD), and Alcohol-associated Liver Disease (ALD) [5]. Group 2: IMPACT Study Details - The IMPACT trial enrolled 212 patients with biopsy-confirmed MASH and fibrosis stages F2/F3, randomized to receive either weekly subcutaneous pemvidutide at doses of 1.2 mg and 1.8 mg or placebo for 24 weeks [3]. - Key efficacy endpoints include MASH resolution or fibrosis improvement at 24 weeks, with secondary endpoints focusing on weight loss and non-invasive tests [3]. - A total of 48 weeks of treatment is planned, with final readout expected in Q4 2025 [3]. Group 3: Pemvidutide Characteristics - Pemvidutide is an investigational peptide-based dual receptor agonist that mimics the effects of diet and exercise on weight loss, suppressing appetite and increasing energy expenditure [4]. - Clinical trials have shown significant MASH resolution, liver fibrosis improvement, and weight loss, along with reductions in liver fat content, triglycerides, LDL cholesterol, and blood pressure [4]. - The U.S. FDA has granted Fast Track designation to pemvidutide for MASH treatment, with ongoing trials for AUD and ALD [4].

Core Insights - Altimmune, Inc. is presenting findings on pemvidutide, a novel GLP-1/glucagon dual receptor agonist, at the American Diabetes Association's 85 Scientific Sessions, focusing on its potential in treating metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD), and alcohol-associated liver disease (ALD) [1][4]. Group 1: Presentation Details - The oral presentation titled "Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight" will be held on June 21, 2025, at 5:45 PM CDT [2]. - Three poster presentations will cover topics including cardiovascular safety, non-invasive tests of central adiposity, and cholesterol transport in a hamster model, all scheduled for June 22, 2025 [2]. Group 2: Pemvidutide Overview - Pemvidutide is designed to activate GLP-1 and glucagon receptors, mimicking the effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure [3]. - Clinical trials have shown that pemvidutide leads to significant weight loss, preservation of lean mass, and reductions in triglycerides, LDL cholesterol, liver fat content, and blood pressure [4]. Group 3: Regulatory Status and Trials - The U.S. FDA has granted Fast Track designation to pemvidutide for MASH treatment, with the MOMENTUM Phase 2 obesity trial completed in 2024 and ongoing IMPACT Phase 2b MASH trial expected to report top line results in Q2 2025 [4]. - IND applications for AUD and ALD have received FDA clearance, with the Phase 2 trial for AUD starting in Q2 2025 and the ALD trial set to begin in Q3 2025 [4]. Group 4: Company Background - Altimmune is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases, with pemvidutide as its lead program [5].